Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Overview of attention for article published in Frontiers in immunology, November 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 8 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 46,560 followers.

RT @FrontImmunol: New Research: Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC en…

11 Nov 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC en…

11 Nov 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC en…

11 Nov 2023

Reply Repost Favourite

New Research: Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers: T cell engagers, a category… https://t.co

11 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.